# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BMO Capital analyst Keith Tapper initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price ...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $51 price target.
High-dose NGN-401 has been well-tolerated, and low-dose NGN-401 continues to show a favorable safety profileInterim safety data...
Baird analyst Joel Beatty initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price Target ...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $51 price target.
As part of the START Program, Neurogene will have opportunities for enhanced communications with the FDA, with the aim to furth...